Blockade and activation of the human neuronal nicotinic acetylcholine receptors by atracurium and laudanosine

Florence Chiodini, Eric Charpantier, Dominique Muller, E. Tassonyi, Thomas Fuchs-Buder, Daniel Bertrand

Research output: Contribution to journalArticle

36 Citations (Scopus)

Abstract

Background: Curaremimetic nondepolarizing muscle relaxants are widely used in clinical practice to prevent muscle contraction either during surgery or during intensive care. Although primarily acting at the neuromuscular junction, these compounds can cause adverse effects, including modification of cardiac rhythm, arterial blood pressure, and in the worst cases, triggering of seizures. In this study, we assessed the interaction of atracurium and its metabolite, laudanosine, with neuronal nicotinic receptors. Methods: The human neuronal nicotinic receptors α4β2, α3β4, α3α5β4, and α7 are heterologously expressed in Xenopus laevis oocytes, and the effect of atracurium and its degradation product, laudanosine, were studied on these receptors. Results: Atracurium and laudanosine inhibited in the micromolar range the major brain α4β2 receptor and the ganglionic α3β4 or α3β4α5 and the homomeric α7 receptors. For all four receptors, inhibition was rapid and readily reversible within less than 1 min. Atracurium blockade was competitive at α4β2 and α7 receptors but displayed a noncompetitive blockade at the α3β4 receptors. Inhibition at this receptor subtype was not modified by α5. Laudanosine was found to have a dual mode of action; first, it competes with acetylcholine and, second, it blocks the ionic pore by steric hindrance. At low concentrations, these two drugs are able to activate both the α4β2 and the α3β4 receptors. Conclusion: Adverse effects observed during atracurium administration may be attributed, at least partly, to an interaction with neuronal nicotinic receptors.

Original languageEnglish
Pages (from-to)643-651
Number of pages9
JournalAnesthesiology
Volume94
Issue number4
Publication statusPublished - 2001

Fingerprint

Atracurium
Nicotinic Receptors
Neuromuscular Junction
Xenopus laevis
Critical Care
Muscle Contraction
Acetylcholine
Oocytes
Arterial Pressure
Seizures
laudanosine
Muscles
Brain
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Anesthesiology and Pain Medicine

Cite this

Chiodini, F., Charpantier, E., Muller, D., Tassonyi, E., Fuchs-Buder, T., & Bertrand, D. (2001). Blockade and activation of the human neuronal nicotinic acetylcholine receptors by atracurium and laudanosine. Anesthesiology, 94(4), 643-651.

Blockade and activation of the human neuronal nicotinic acetylcholine receptors by atracurium and laudanosine. / Chiodini, Florence; Charpantier, Eric; Muller, Dominique; Tassonyi, E.; Fuchs-Buder, Thomas; Bertrand, Daniel.

In: Anesthesiology, Vol. 94, No. 4, 2001, p. 643-651.

Research output: Contribution to journalArticle

Chiodini, F, Charpantier, E, Muller, D, Tassonyi, E, Fuchs-Buder, T & Bertrand, D 2001, 'Blockade and activation of the human neuronal nicotinic acetylcholine receptors by atracurium and laudanosine', Anesthesiology, vol. 94, no. 4, pp. 643-651.
Chiodini, Florence ; Charpantier, Eric ; Muller, Dominique ; Tassonyi, E. ; Fuchs-Buder, Thomas ; Bertrand, Daniel. / Blockade and activation of the human neuronal nicotinic acetylcholine receptors by atracurium and laudanosine. In: Anesthesiology. 2001 ; Vol. 94, No. 4. pp. 643-651.
@article{abb4de6758c64810bf18f22799c981b1,
title = "Blockade and activation of the human neuronal nicotinic acetylcholine receptors by atracurium and laudanosine",
abstract = "Background: Curaremimetic nondepolarizing muscle relaxants are widely used in clinical practice to prevent muscle contraction either during surgery or during intensive care. Although primarily acting at the neuromuscular junction, these compounds can cause adverse effects, including modification of cardiac rhythm, arterial blood pressure, and in the worst cases, triggering of seizures. In this study, we assessed the interaction of atracurium and its metabolite, laudanosine, with neuronal nicotinic receptors. Methods: The human neuronal nicotinic receptors α4β2, α3β4, α3α5β4, and α7 are heterologously expressed in Xenopus laevis oocytes, and the effect of atracurium and its degradation product, laudanosine, were studied on these receptors. Results: Atracurium and laudanosine inhibited in the micromolar range the major brain α4β2 receptor and the ganglionic α3β4 or α3β4α5 and the homomeric α7 receptors. For all four receptors, inhibition was rapid and readily reversible within less than 1 min. Atracurium blockade was competitive at α4β2 and α7 receptors but displayed a noncompetitive blockade at the α3β4 receptors. Inhibition at this receptor subtype was not modified by α5. Laudanosine was found to have a dual mode of action; first, it competes with acetylcholine and, second, it blocks the ionic pore by steric hindrance. At low concentrations, these two drugs are able to activate both the α4β2 and the α3β4 receptors. Conclusion: Adverse effects observed during atracurium administration may be attributed, at least partly, to an interaction with neuronal nicotinic receptors.",
author = "Florence Chiodini and Eric Charpantier and Dominique Muller and E. Tassonyi and Thomas Fuchs-Buder and Daniel Bertrand",
year = "2001",
language = "English",
volume = "94",
pages = "643--651",
journal = "Anesthesiology",
issn = "0003-3022",
publisher = "Lippincott Williams and Wilkins",
number = "4",

}

TY - JOUR

T1 - Blockade and activation of the human neuronal nicotinic acetylcholine receptors by atracurium and laudanosine

AU - Chiodini, Florence

AU - Charpantier, Eric

AU - Muller, Dominique

AU - Tassonyi, E.

AU - Fuchs-Buder, Thomas

AU - Bertrand, Daniel

PY - 2001

Y1 - 2001

N2 - Background: Curaremimetic nondepolarizing muscle relaxants are widely used in clinical practice to prevent muscle contraction either during surgery or during intensive care. Although primarily acting at the neuromuscular junction, these compounds can cause adverse effects, including modification of cardiac rhythm, arterial blood pressure, and in the worst cases, triggering of seizures. In this study, we assessed the interaction of atracurium and its metabolite, laudanosine, with neuronal nicotinic receptors. Methods: The human neuronal nicotinic receptors α4β2, α3β4, α3α5β4, and α7 are heterologously expressed in Xenopus laevis oocytes, and the effect of atracurium and its degradation product, laudanosine, were studied on these receptors. Results: Atracurium and laudanosine inhibited in the micromolar range the major brain α4β2 receptor and the ganglionic α3β4 or α3β4α5 and the homomeric α7 receptors. For all four receptors, inhibition was rapid and readily reversible within less than 1 min. Atracurium blockade was competitive at α4β2 and α7 receptors but displayed a noncompetitive blockade at the α3β4 receptors. Inhibition at this receptor subtype was not modified by α5. Laudanosine was found to have a dual mode of action; first, it competes with acetylcholine and, second, it blocks the ionic pore by steric hindrance. At low concentrations, these two drugs are able to activate both the α4β2 and the α3β4 receptors. Conclusion: Adverse effects observed during atracurium administration may be attributed, at least partly, to an interaction with neuronal nicotinic receptors.

AB - Background: Curaremimetic nondepolarizing muscle relaxants are widely used in clinical practice to prevent muscle contraction either during surgery or during intensive care. Although primarily acting at the neuromuscular junction, these compounds can cause adverse effects, including modification of cardiac rhythm, arterial blood pressure, and in the worst cases, triggering of seizures. In this study, we assessed the interaction of atracurium and its metabolite, laudanosine, with neuronal nicotinic receptors. Methods: The human neuronal nicotinic receptors α4β2, α3β4, α3α5β4, and α7 are heterologously expressed in Xenopus laevis oocytes, and the effect of atracurium and its degradation product, laudanosine, were studied on these receptors. Results: Atracurium and laudanosine inhibited in the micromolar range the major brain α4β2 receptor and the ganglionic α3β4 or α3β4α5 and the homomeric α7 receptors. For all four receptors, inhibition was rapid and readily reversible within less than 1 min. Atracurium blockade was competitive at α4β2 and α7 receptors but displayed a noncompetitive blockade at the α3β4 receptors. Inhibition at this receptor subtype was not modified by α5. Laudanosine was found to have a dual mode of action; first, it competes with acetylcholine and, second, it blocks the ionic pore by steric hindrance. At low concentrations, these two drugs are able to activate both the α4β2 and the α3β4 receptors. Conclusion: Adverse effects observed during atracurium administration may be attributed, at least partly, to an interaction with neuronal nicotinic receptors.

UR - http://www.scopus.com/inward/record.url?scp=0035095777&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035095777&partnerID=8YFLogxK

M3 - Article

C2 - 11379686

AN - SCOPUS:0035095777

VL - 94

SP - 643

EP - 651

JO - Anesthesiology

JF - Anesthesiology

SN - 0003-3022

IS - 4

ER -